{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"55"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"206"},{"groupId":"OG002","value":"183"},{"groupId":"OG003","value":"488"}],"units":"Participants"}],"description":"To study whether intensifying induction, including fractionated cyclophosphamide and thioguanine, in patients with day 15 MRD ≥ 5% will result in improved leukemia cytoreduction in this subgroup compared to therapy followed in the TOTXV protocol.","groups":[{"description":"Patients randomized on the first day of continuation phase to receive 3500 units/m\\^2 dose of PEG-asparaginase","id":"OG000","title":"TOTXVI PEG 3500"},{"description":"Patients randomized on the first day of continuation phase to receive 2,500 units/m\\^2 dose of PEG-asparaginase","id":"OG001","title":"TOTXVI PEG 2500"},{"description":"Patients who came off study prior to randomization","id":"OG002","title":"TOTXVI Not Randomized"},{"description":"Eligible Patients in TOTXV","id":"OG003","title":"All Eligible Patients in TOTXV"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis will compare the proportion of TOTXV patients who had Day-19 MRD≥5% with the proportion of patients on TOTXVI with Day-15 MRD≥5%.","reportingStatus":"POSTED","timeFrame":"Middle of remission induction, Day 15 in Total XVI and Day 19 in Total XV","title":"Proportion of Participants With Minimal Residual Disease (MRD) on the 15th Day of Remission Induction ≥ 5%","type":"SECONDARY","unitOfMeasure":"Participants"}